Hemostemix Issues Corporate Update From CEO Elmar Burchardt—hemostemix.com/pages/posts/h…
Hemostemix Company Information Now Available Through S&P Capital IQ Corporation Records Program—hemostemix.com/pages/posts/h…
Hemostemix to Present at Phacilitate Cell & Gene Therapy World 2016 in Washington, D.C. on January 25. —hemostemix.com/pages/posts/h…
Hemostemix announced today that it has commenced trading on the OTCQX marketplace under the symbol “HMTXF.”—hemostemix.com/pages/posts/h…
Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States—hemostemix.com/pages/posts/h…
Hemostemix Announces Company Updates and Attendance at the J.P. Morgan 34th Annual Healthcare Conference—hemostemix.com/pages/posts/h…
1
Hemostemix Names Jim Brown, CEO of Hemostemix Asia, Inc., to Board of Directors—hemostemix.com/pages/posts/h…
2
Hemostemix Engages Wolverton Securities Ltd. for Brokered Private Placement Offering —hemostemix.com/pages/posts/h…
Dr. Rahul Sarugaser, Hemostemix VP of corporate development, to present at 2015 Stem Cell Meeting on the Mesa—hemostemix.com/pages/posts/h…
1
Hemostemix Executes Strategic Alliance with Hemostemix Asia To Expand Phase-2 Trial for Treating CLI to Taiwan—hemostemix.com/pages/posts/h…
Hemostemix management & members of the Company's Data Safety Monitoring Board for its phase-2 clinical trial for CLI.
Hemostemix Holds First Meeting of Data Safety Monitoring Board (DSMB) for Phase-2 Clinical Trial for CLI—hemostemix.com/index.php/tra…
Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the U.S.—hemostemix.com/index.php/tra…
Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia—hemostemix.com/index.php/tra…
Hemostemix forms strategic alliance in Asia for treating critical limb ischemia in Taiwan, China, and South Korea—hemostemix.com/index.php/tra…
Hemostemix Posts Corporate Presentation on Company Website—hemostemix.com/index.php/cor…
Hemostemix Enrolls 5th Participant at Vancouver General Hospital in Phase-2 Clinical Trial for Critical Limb Ischemia—hemostemix.com/index.php/tra…
Hemostemix Prepares IND Application for U.S. FDA Review for ACP-01 to Treat Critical Limb Ischemia—
hemostemix.com/index.php/tra…
1
Hemostemix and Ludwig Boltzmann Institute Enter Research Collaboration Agreement to Study Applications of ACP-01— hemostemix.com/index.php/tra…


